Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Editorial

Metabolic dysfunction in patients following DAA-induced viral cure for HCV infection: A non-negligible risk to liver-related health: Editorial on “Adverse impact of metabolic dysfunction on fibrosis regression following direct-acting antiviral therapy: A multicenter study for chronic hepatitis C”

Chen-Hua Liu, Yu-Ping Chang

Clin Mol Hepatol. 2025;31(2):658-661. Published online February 17, 2025

DOI: https://doi.org/10.3350/cmh.2025.0155

View: 1029 Download: 45 Web of Science: 2 Crossref: 2

Reconsidering treatment indications for chronic hepatitis B: Insights from the TORCH-B roll-over study: Editorial on “Antiviral therapy for chronic hepatitis B with mildly elevated aminotransferase: A rollover study from the TORCH-B trial”

Chih-Wen Wang, Ming-Lung Yu

Clin Mol Hepatol. 2025;31(2):606-609. Published online December 3, 2024

DOI: https://doi.org/10.3350/cmh.2024.1078

View: 1296 Download: 32 Web of Science: 1 Crossref: 1

Momentum towards simplifying and expanding treatment for chronic hepatitis B: The body of evidence continues to grow: Editorial on “Antiviral therapy for chronic hepatitis B with mildly elevated aminotransferase: A rollover study from the TORCH-B trial”

Robert J. Wong

Clin Mol Hepatol. 2025;31(2):603-605. Published online October 29, 2024

DOI: https://doi.org/10.3350/cmh.2024.0929

View: 986 Download: 28 Web of Science: 1 Crossref: 1

Universal self-testing as a cost-effective weapon to eliminate hepatitis C virus in the Republic of Korea: Editorial on “Self-testing strategy to eliminate hepatitis C as per World Health Organization’s goal: Analysis of disease burden and cost-effectiveness”

Eun Sun Jang

Clin Mol Hepatol. 2025;31(2):596-598. Published online November 11, 2024

DOI: https://doi.org/10.3350/cmh.2024.0992

View: 1072 Download: 23 Web of Science: 1 Crossref: 1

Original Article

Adverse impact of metabolic dysfunction on fibrosis regression following direct-acting antiviral therapy: A multicenter study for chronic hepatitis C

Tom Ryu, Young Chang, Soung Won Jeong, Jeong-Ju Yoo, Sae Hwan Lee, Sang Gyune Kim, Young Seok Kim, Hong Soo Kim, Seung Up Kim, Jae Young Jang

Clin Mol Hepatol. 2025;31(2):548-562. Published online January 9, 2025

DOI: https://doi.org/10.3350/cmh.2024.0904

View: 1791 Download: 121 Web of Science: 4 Crossref: 1

Male preference for TERT alterations and HBV integration in young-age HBV-related HCC: implications for sex disparity

Jin Seoub Kim, Hye Seon Kim, Kwon Yong Tak, Ji Won Han, Heechul Nam, Pil Soo Sung, Sung Won Lee, Jung Hyun Kwon, Si Hyun Bae, Jong Young Choi, Seung Kew Yoon, Jeong Won Jang

Clin Mol Hepatol. 2025;31(2):509-524. Published online January 2, 2025

DOI: https://doi.org/10.3350/cmh.2024.0545

View: 2076 Download: 140 Web of Science: 1 Crossref: 1

Longitudinal profile of plasma pregenomic RNA in patients with chronic hepatitis B infection on long-term nucleoside analogues and its interaction with clinical parameters

Lung-Yi Mak, Mark Anderson, Michael Stec, Matthew Shing-Hin Chung, Danny Ka-Ho Wong, Rex Wan-Hin Hui, Wai-Kay Seto, Gavin Cloherty, Man-Fung Yuen

Clin Mol Hepatol. 2025;31(2):460-473. Published online December 26, 2024

DOI: https://doi.org/10.3350/cmh.2024.0724

View: 1628 Download: 124

Cost-effectiveness and return on investment of hepatitis C virus elimination in China: A modelling study

Meiyu Wu, Jing Ma, Xuehong Wang, Sini Li, Chongqing Tan, Ouyang Xie, Andong Li, Aaron G Lim, Xiaomin Wan

Clin Mol Hepatol. 2025;31(2):394-408. Published online December 3, 2024

DOI: https://doi.org/10.3350/cmh.2024.0664

View: 2207 Download: 176 Crossref: 1

Correspondence

Correspondence to letter to the editor on “Contemporary awareness of viral hepatitis between 2012 and 2022 among Korean adults”

Chang Hun Lee, In Hee Kim, Sook-Hyang Jeong

Clin Mol Hepatol. 2025;31(2):e149-e151. Published online November 6, 2024

DOI: https://doi.org/10.3350/cmh.2024.0944

View: 1114 Download: 20

HCV self-testing: Bridging screening gaps and ensuring cost-effectiveness for both high-risk and universal populations: Correspondence to editorial on “Self-testing strategy to eliminate hepatitis C as per World Health Organization’s goal: Analysis of disease burden and cost-effectiveness”

Gyeongseon Shin, Beom Kyung Kim, SeungJin Bae, Hankil Lee, Sang Hoon Ahn

Clin Mol Hepatol. 2025;31(2):e163-e165. Published online November 29, 2024

DOI: https://doi.org/10.3350/cmh.2024.1057

View: 1026 Download: 37

Letter to the Editor

Treatment response to nucleos(t)ide analogs in chronic hepatitis B with mildly elevated alanine aminotransferase: Letter to the editor on “Antiviral therapy for chronic hepatitis B with mildly elevated aminotransferase: A rollover study from the TORCH-B trial”

Jian Wang, Fei Cao, Chuanwu Zhu, Chao Wu, Rui Huang

Clin Mol Hepatol. 2025;31(2):e140-e142. Published online December 3, 2024

DOI: https://doi.org/10.3350/cmh.2024.0960

View: 1062 Download: 30 Web of Science: 1 Crossref: 1

Global inequality in the burden of hepatitis B from 1990 to 2021: Findings from the global burden of disease study 2021: Letter to the editor on “Comprehensive approach to controlling chronic hepatitis B in China”

Chunlong Liu, Jiangtao Yu

Clin Mol Hepatol. 2025;31(2):e134-e136. Published online December 17, 2024

DOI: https://doi.org/10.3350/cmh.2024.1085

View: 1430 Download: 85 Web of Science: 1 Crossref: 1

Correspondence

Expanding treatment eligibility for chronic hepatitis B: Balancing benefits, limitations, and healthcare access: Correspondence to editorial on “Antiviral therapy for chronic hepatitis B with mildly elevated aminotransferase: A rollover study from the TORCH-B trial”

Yao-Chun Hsu, Chi-Yi Chen, Jaw-Town Lin

Clin Mol Hepatol. 2025;31(2):e169-e172. Published online December 23, 2024

DOI: https://doi.org/10.3350/cmh.2024.1138

View: 1004 Download: 26

Correspondence to editorial on “Adverse impact of metabolic dysfunction on fibrosis regression following direct-acting antiviral therapy: A multicenter study for chronic hepatitis C”

Tom Ryu, Young Chang, Seung Up Kim, Jae Young Jang

Clin Mol Hepatol. 2025;31(2):e203-e205. Published online February 24, 2025

DOI: https://doi.org/10.3350/cmh.2025.0179

View: 789 Download: 19 Web of Science: 1 Crossref: 1

Reply to Correspondence

Reply to correspondence on “Adverse impact of metabolic dysfunction on fibrosis regression following direct-acting antiviral therapy: A multicenter study for chronic hepatitis C”

Chen-Hua Liu, Yu-Ping Chang

Clin Mol Hepatol. 2025;31(2):e232-e233. Published online February 26, 2025

DOI: https://doi.org/10.3350/cmh.2025.0203

View: 775 Download: 22

Review

Prospect of emerging treatments for hepatitis B virus functional cure

Rex Wan-Hin Hui, Lung-Yi Mak, James Fung, Wai-Kay Seto, Man-Fung Yuen

Clin Mol Hepatol. 2025;31(Suppl):S165-181. Published online November 14, 2024

DOI: https://doi.org/10.3350/cmh.2024.0855

View: 2812 Download: 393 Web of Science: 5 Crossref: 7

Mechanisms of hepatocellular carcinoma and cirrhosis development in concurrent steatotic liver disease and chronic hepatitis B

Saisai Zhang, Lung-Yi Mak, Man-Fung Yuen, Wai-Kay Seto

Clin Mol Hepatol. 2025;31(Suppl):S182-S195. Published online November 21, 2024

DOI: https://doi.org/10.3350/cmh.2024.0837

View: 2440 Download: 184 Web of Science: 2 Crossref: 2

Update on the treatment navigation for functional cure of chronic hepatitis B: Expert consensus 2.0

Di Wu, Jia-Horng Kao, Teerha Piratvisuth, Xiaojing Wang, Patrick T.F. Kennedy, Motoyuki Otsuka, Sang Hoon Ahn, Yasuhito Tanaka, Guiqiang Wang, Zhenghong Yuan, Wenhui Li, Young-Suk Lim, Junqi Niu, Fengmin Lu, Wenhong Zhang, Zhiliang Gao, Apichat Kaewdech, Meifang Han, Weiming Yan, Hong Ren, Peng Hu, Sainan Shu, Paul Yien Kwo, Fu-sheng Wang, Man-Fung Yuen, Qin Ning

Clin Mol Hepatol. 2025;31(Suppl):S134-S164. Published online January 22, 2025

DOI: https://doi.org/10.3350/cmh.2024.0780

View: 3785 Download: 416 Web of Science: 1 Crossref: 2

Editorial

MASLD after hepatitis C virus eradication: Do not overlook the cardiometabolic risk factors: Editorial on “Dynamic change of metabolic dysfunction-associated steatotic liver disease in chronic hepatitis C patients after viral eradication: A nationwide registry study in Taiwan”

Rex Wan-Hin Hui, Lung-Yi Mak

Clin Mol Hepatol. 2025;31(1):290-292. Published online August 7, 2024

DOI: https://doi.org/10.3350/cmh.2024.0630

View: 1265 Download: 33 Crossref: 2

The use of transient elastography for predicting hepatocellular carcinoma in chronic hepatitis B patients: Editorial on “Risk assessment of hepatitis B virus-related hepatocellular carcinoma development using vibration-controlled transient elastography: Systematic review and meta-analysis”

Mirko Zoncapè, Emmanuel A. Tsochatzis

Clin Mol Hepatol. 2025;31(1):268-274. Published online September 24, 2024

DOI: https://doi.org/10.3350/cmh.2024.0817

View: 1522 Download: 54 Web of Science: 2 Crossref: 2

Original Article

Antiviral therapy for chronic hepatitis B with mildly elevated aminotransferase: A rollover study from the TORCH-B trial

Yao-Chun Hsu, Chi-Yi Chen, Cheng-Hao Tseng, Chieh-Chang Chen, Teng-Yu Lee, Ming-Jong Bair, Jyh-Jou Chen, Yen-Tsung Huang, I-Wei Chang, Chi-Yang Chang, Chun-Ying Wu, Ming-Shiang Wu, Lein-Ray Mo, Jaw-Town Lin

Clin Mol Hepatol. 2025;31(1):213-226. Published online October 17, 2024

DOI: https://doi.org/10.3350/cmh.2024.0640

View: 2152 Download: 166 Web of Science: 4

Self-testing strategy to eliminate hepatitis C as per World Health Organization’s goal: Analysis of disease burden and cost-effectiveness

Gyeongseon Shin, Beom Kyung Kim, SeungJin Bae, Hankil Lee, Sang Hoon Ahn

Clin Mol Hepatol. 2025;31(1):166-178. Published online October 4, 2024

DOI: https://doi.org/10.3350/cmh.2024.0484

View: 1956 Download: 142 Web of Science: 3 Crossref: 4

Correspondence

Correspondence to letter to the editor on “Non-linear association between liver fibrosis scores and viral load in patients with chronic hepatitis B”

Gi-Ae Kim, Seung Won Choi, Young-Suk Lim

Clin Mol Hepatol. 2025;31(1):e108-e109. Published online August 5, 2024

DOI: https://doi.org/10.3350/cmh.2024.0619

View: 1230 Download: 35

Letter to the Editor

Presence of liver fibrosis in chronic hepatitis B patients with varying serum hepatitis B virus DNA levels: Letter to the editor on “Non-linear association between liver fibrosis scores and viral load in patients with chronic hepatitis B”

Jian Wang, Shaoqiu Zhang, Chuanwu Zhu, Yuanwang Qiu, Chao Wu, Rui Huang

Clin Mol Hepatol. 2025;31(1):e27-e30. Published online August 7, 2024

DOI: https://doi.org/10.3350/cmh.2024.0602

View: 1323 Download: 52 Crossref: 1

Correspondence

Steatotic liver disease in chronic hepatitis C related hepatocellular carcinoma: Inflictor or bystander?: Correspondence to editorial on “Dynamic change of metabolic dysfunction-associated steatotic liver disease in chronic hepatitis C patients after viral eradication: A nationwide registry study in Taiwan”

Chung-Feng Huang, Ming-Lun Yeh, Chia-Yen Dai, Jee-Fu Huang, Wan-Long Chuang, Ming-Lung Yu

Clin Mol Hepatol. 2025;31(1):e64-e66. Published online August 19, 2024

DOI: https://doi.org/10.3350/cmh.2024.0638

View: 1394 Download: 53 Web of Science: 1 Crossref: 1

Correspondence to editorial on “Risk assessment of hepatitis B virus-related hepatocellular carcinoma development using vibration-controlled transient elastography: Systematic review and meta-analysis”

Young-Joo Jin, Seung Up Kim

Clin Mol Hepatol. 2025;31(1):e55-e57. Published online October 7, 2024

DOI: https://doi.org/10.3350/cmh.2024.0846

View: 1123 Download: 26 Web of Science: 1 Crossref: 1

Letter to the Editor

Contemporary awareness of viral hepatitis between 2012 and 2022 among Korean adults

Donghee Kim, Won Kim, Aijaz Ahmed

Clin Mol Hepatol. 2025;31(1):e5-e7. Published online October 8, 2024

DOI: https://doi.org/10.3350/cmh.2024.0849

View: 1203 Download: 45 Web of Science: 1 Crossref: 1

Chronic hepatitis B, extrahepatic malignancies and the use of antiviral drugs

Meng-Che Wu, Shih-Chi Yang, Shuo-Yan Gau

Clin Mol Hepatol. 2025;31(1):e19-e20. Published online October 17, 2024

DOI: https://doi.org/10.3350/cmh.2024.0906

View: 1067 Download: 35

Reply to Correspondence

Reply to correspondence on “Risk assessment of hepatitis B virus-related hepatocellular carcinoma development using vibration-controlled transient elastography: Systematic review and meta-analysis”

Mirko Zoncapè, Emmanuel A. Tsochatzis

Clin Mol Hepatol. 2025;31(1):e117-e118. Published online November 11, 2024

DOI: https://doi.org/10.3350/cmh.2024.0994

View: 1082 Download: 21

Letter to the Editor

Comment: Non-invasive prediction of post-sustained virological response hepatocellular carcinoma in hepatitis C virus

Xinpu Miao, Haidong Wu, Jinrong Xu, Wei Cheng

Clin Mol Hepatol. 2025;31(1):e23-e24. Published online November 26, 2024

DOI: https://doi.org/10.3350/cmh.2024.1035

View: 1054 Download: 25

Viewed By 13031	Epidemiology of metabolic dysfunction-associated steatotic liver disease
Viewed By 7838	Radiogenomics of intrahepatic cholangiocarcinoma predicts immunochemotherapy response and identifies therapeutic target
Viewed By 7348	MAFLD: How is it different from NAFLD?
Viewed By 5906	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Viewed By 5847	Hepatocellular carcinoma: updates on epidemiology, surveillance, diagnosis and treatment

Cited By 369	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Cited By 357	Global incidence and prevalence of nonalcoholic fatty liver disease
Cited By 237	MAFLD: How is it different from NAFLD?
Cited By 122	Non-alcoholic fatty liver disease: Definition and subtypes
Cited By 118	Pathogenesis and treatment of non-alcoholic steatohepatitis and its fibrosis

Viral hepatitis